References
- Sercarz E E, Lehmann P V, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 1993; 11: 729
- Tsai V, Kawashima I, Keogh E, Daly K, Sette A, Celis E. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. Crit Rev Immuno. 1998; 18: 65
- Wentworth P A, Celis E, Crimi C, Stitely S, Hale L, Tsai V, Serra H M, del Guercio M.F., Livingston B, Alazard D, Fikes J, Kubo R T, Grey H M, Chesnut R W, Chisari F V, Sette A. In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides. Molec. Immunol. 1995; 32: 603
- Celis E, Tsai V, Crimi C, DeMars R, Wentworth P A, Chesnut R W, Grey H M, Sette A, Serra H.M. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. (USA. 1994; 91: 2105
- Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacker B, Konwalkinka G, Fritsch P O, Steinman RM, Schuler G. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 1994; 180: 83
- Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Me. 1994; 179: 1109
- Kawashima I, Hudson S, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Human Immunol. 1998; 59: 1
- Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E. Identification of subdominant CTL epitopes of the gp100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 1997; 158: 1796
- De Plaen E, Arden K, Traversari C, Gaforio J J, Szikora J.-P, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C, Brasseur R, Chomez P, De Backer O, Cavenee W, Boon T. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenet 1994; 40: 360
- Russo V, Traversari C, Verrecchia A, Mottolese M, Natali P G, Bordignon C. Expression of the MAGE gene family in primary and metastatic human breast cancer. Implications for tumor antigen-specific immunotherapy. Int. J. Cance. 1995; 64: 216
- Weynants P, Lethe B, Brasseur F, Marchand M, Boon T. Expression of MAGE genes by non-small-cell lung carcinomas. Int. J. Cance. 1994; 56: 826
- Traversari C, van der Bruggen P., Luescher I F, Lurquin C, Chomez P, Van Pel A., De Plaen E., Amar-Costesec A, Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 1992; 176: 1453
- van der Bruggen P, Szikora J P, Boel P, Wildmann C, Somville M, Sensi M, Boon T. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw* 1601. Eur J Immunol 1994; 24: 2134
- van der Bruggen P, Bastin J, Gajewski T, Coulie P G, Boel P, De Smet C., Traversari C, Townsend A, Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immuno. 1994; 24: 3038
- Gaugler B, Van den Eynde B., van der Bruggen P., Romero P, Gaforio J J, De Plaen E., Lethe B, Brasseur F, Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Me. 1994; 179: 921
- Fleischhauer K, Fruci D, Van Endert P., Herman J, Tanzarella S, Wallny H J, Coulie P, Bordignon C, Traversari C. Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. Int. J. Cance. 1996; 68: 622